MX2017001908A - Metodo para el tratamiento de la depresion. - Google Patents
Metodo para el tratamiento de la depresion.Info
- Publication number
- MX2017001908A MX2017001908A MX2017001908A MX2017001908A MX2017001908A MX 2017001908 A MX2017001908 A MX 2017001908A MX 2017001908 A MX2017001908 A MX 2017001908A MX 2017001908 A MX2017001908 A MX 2017001908A MX 2017001908 A MX2017001908 A MX 2017001908A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- depression
- patient
- allele
- esketamine
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
- Otolaryngology (AREA)
Abstract
La presente invención se refiere a un método para el tratamiento de la depresión, por ejemplo, la depresión resistente al tratamiento; en donde el régimen de tratamiento se ajusta en dependencia de del genotipo del paciente en el polimorfismo de un solo nucleótido (SNP) rs4306882; específicamente, el método comprende determinar la presencia de un alelo G o T en rs4306882, y la administración de un régimen de dosificación de ketamina o esketamina, en donde el régimen de dosificación se ajusta para proporcionar una dosis más alta y/o de mayor frecuencia de la ketamina o la esketamina a aquellos pacientes con el alelo G (en lugar del alelo T) en el sitio polimórfico de rs4306882; adicionalmente, se describe un método para predecir si un paciente que sufre de depresión está predispuesto genéticamente a responder probablemente a los antidepresivos que bloquean la recaptura de los neurotransmisores monoamina, que comprende el genotipado de dicho paciente para determinar el genotipo del paciente en el SNP rs4306882.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462036896P | 2014-08-13 | 2014-08-13 | |
| PCT/US2015/044830 WO2016025581A1 (en) | 2014-08-13 | 2015-08-12 | Method for the treatment of depression |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2017001908A true MX2017001908A (es) | 2017-08-08 |
Family
ID=55301311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017001908A MX2017001908A (es) | 2014-08-13 | 2015-08-12 | Metodo para el tratamiento de la depresion. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10098854B2 (es) |
| EP (1) | EP3179993B1 (es) |
| JP (1) | JP6545788B2 (es) |
| KR (1) | KR20170040800A (es) |
| CN (1) | CN106714789A (es) |
| AU (2) | AU2015301782B2 (es) |
| CA (1) | CA2957926A1 (es) |
| IL (2) | IL250490A0 (es) |
| MA (1) | MA40462A (es) |
| MX (1) | MX2017001908A (es) |
| WO (1) | WO2016025581A1 (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014240102A1 (en) | 2013-03-15 | 2015-09-17 | Janssen Pharmaceutica Nv | Pharmaceutical composition of S-ketamine hydrochloride |
| HUE056378T2 (hu) | 2013-09-13 | 2022-02-28 | Univ Chiba Nat Univ Corp | R-Ketamin és sójának alkalmazása gyógyszerekként |
| EP3094312B1 (en) * | 2014-01-14 | 2019-03-13 | Children's Hospital Medical Center | Compositions comprising ketamine for treating an autism spectrum disorder |
| US20160074340A1 (en) | 2014-09-15 | 2016-03-17 | Janssen Pharmaceutica Nv | VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION |
| US9844551B2 (en) | 2015-01-14 | 2017-12-19 | Children's Hospital Medical Center | Compositions and methods for treatment of fragile X syndrome |
| US11191734B2 (en) | 2015-06-27 | 2021-12-07 | Shenox Pharmaceuticals, Llc | Ketamine transdermal delivery system |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| US11491120B2 (en) | 2017-11-09 | 2022-11-08 | The Trustees Of Columbia University In The City Of New York | Pharmacological prophylactics against stress-induced affective disorders in females |
| WO2019094596A1 (en) | 2017-11-09 | 2019-05-16 | The Trustees Of Columbia University In The City Of New York | Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders |
| CN117531017A (zh) * | 2017-12-22 | 2024-02-09 | 詹森药业有限公司 | 用于治疗抑郁症的艾司氯胺酮 |
| WO2019160057A1 (ja) | 2018-02-15 | 2019-08-22 | 国立大学法人千葉大学 | 炎症性疾患若しくは骨疾患の予防又は治療剤及び医薬組成物 |
| EP3813808A4 (en) | 2018-05-04 | 2022-01-26 | Perception Neuroscience, Inc. | DRUG TREATMENT METHODS |
| AU2020210904A1 (en) | 2019-01-23 | 2021-08-05 | The Regents Of The University Of Michigan | Pharmacogenomic decision support for modulators of the NMDA, glycine, and AMPA receptors |
| WO2020178653A1 (en) | 2019-03-05 | 2020-09-10 | Janssen Pharmaceuticals, Inc. | Esketamine for the treatment of depression |
| WO2021262871A1 (en) * | 2020-06-25 | 2021-12-30 | Greenway Dna Inc. | Methods and systems for providing a personalized treatment regimen using cannabinoid or psychedelic compounds |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH535201A (de) | 1969-12-19 | 1973-03-31 | Bristol Myers Co | Verfahren zur Spaltung von racemischen 2-(o-Chlorphenyl)-2-methylaminocyclohexanon in die optisch-aktiven Isomeren |
| JPS632932A (ja) | 1986-06-23 | 1988-01-07 | Teijin Ltd | 経鼻投与用粉末状組成物 |
| DE4312016A1 (de) | 1993-04-13 | 1994-10-20 | Goedecke Ag | Stabile Ketamin-Lösungen |
| US5543434A (en) | 1994-02-25 | 1996-08-06 | Weg; Stuart L. | Nasal administration of ketamine to manage pain |
| DE19619665C2 (de) | 1996-05-15 | 2001-03-08 | Goedecke Ag | Racemattrennung von Ketamin |
| RU2224523C2 (ru) | 1998-07-24 | 2004-02-27 | Сео Хонг Ю | Водный раствор, содержащий желчную кислоту, и способ его получения |
| US6176242B1 (en) | 1999-04-30 | 2001-01-23 | Medtronic Inc | Method of treating manic depression by brain infusion |
| EP1103256A1 (de) | 1999-11-26 | 2001-05-30 | Claudius Dr. med. Böck | Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom |
| US7973043B2 (en) | 2002-07-30 | 2011-07-05 | Peter Migaly | Combination therapy for depression, prevention of suicide, and various medical and psychiatric conditions |
| US7273889B2 (en) | 2002-09-25 | 2007-09-25 | Innovative Drug Delivery Systems, Inc. | NMDA receptor antagonist formulation with reduced neurotoxicity |
| US7687080B2 (en) | 2002-11-25 | 2010-03-30 | Taraxos Inc. | Treatment of neuropathy |
| US20040214215A1 (en) | 2003-03-07 | 2004-10-28 | Yu Ruey J. | Bioavailability and improved delivery of alkaline pharmaceutical drugs |
| US20060276550A1 (en) | 2005-06-03 | 2006-12-07 | Dileep Bhagwat | Topical compositions of ketamine and butamben and methods of their use |
| JP2009530385A (ja) * | 2006-03-22 | 2009-08-27 | マウント シナイ スクール オブ メディシン | うつ病の治療のためのケタミンの鼻内投与 |
| RU2008150624A (ru) | 2006-05-22 | 2010-06-27 | Ванда Фармасьютиклз, Инк. (Us) | Лечение депрессивных расстройств |
| DE102007009888A1 (de) * | 2007-02-28 | 2008-09-04 | Hermann, Holger Lars, Dr. | Verwendung von S-(+)-Ketamin zur Behandlung von Depressionen |
| US8710070B2 (en) | 2008-03-27 | 2014-04-29 | University Of Kentucky Research Foundation | Opioid-ketamine and norketamine codrug combinations for pain management |
| US20120225949A1 (en) | 2009-08-14 | 2012-09-06 | Demitri Papalos | Compositions and methods for treating bipolar disorder |
| US20110038807A1 (en) | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
| US8846765B2 (en) | 2010-06-15 | 2014-09-30 | Gruenenthal Gmbh | Pharmaceutical combination |
| MX354547B (es) | 2011-11-14 | 2018-03-09 | Alfasigma Spa | Ensayos y métodos para seleccionar un regimen de tratamiento para un sujeto con depresión. |
| MX2014010939A (es) | 2012-03-12 | 2014-11-13 | Janssen Pharmaceutica Nv | Esketamina para el tratamiento de la depresion refractaria al tratamiento o resistente al tratamiento. |
| BR112015003796A2 (pt) | 2012-08-23 | 2017-07-04 | L Weg Stuart | composição ansiolítica, formulação e método de uso |
| WO2014169272A1 (en) | 2013-04-12 | 2014-10-16 | Icahn School Of Medicine At Mount Sinai | Method for treating post-traumatic stress disorder |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| US20160338977A1 (en) | 2015-05-20 | 2016-11-24 | Janssen Pharmaceutica Nv | Methods and kits for treating depression |
-
2015
- 2015-08-12 WO PCT/US2015/044830 patent/WO2016025581A1/en active Application Filing
- 2015-08-12 US US14/824,513 patent/US10098854B2/en active Active
- 2015-08-12 KR KR1020177006277A patent/KR20170040800A/ko not_active Application Discontinuation
- 2015-08-12 EP EP15831762.8A patent/EP3179993B1/en active Active
- 2015-08-12 JP JP2017507823A patent/JP6545788B2/ja active Active
- 2015-08-12 MX MX2017001908A patent/MX2017001908A/es unknown
- 2015-08-12 CA CA2957926A patent/CA2957926A1/en not_active Abandoned
- 2015-08-12 AU AU2015301782A patent/AU2015301782B2/en not_active Ceased
- 2015-08-12 MA MA040462A patent/MA40462A/fr unknown
- 2015-08-12 CN CN201580043454.XA patent/CN106714789A/zh active Pending
-
2017
- 2017-02-07 IL IL250490A patent/IL250490A0/en active IP Right Grant
-
2020
- 2020-12-03 AU AU2020281101A patent/AU2020281101A1/en not_active Abandoned
- 2020-12-21 IL IL279627A patent/IL279627A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020281101A1 (en) | 2021-01-07 |
| EP3179993B1 (en) | 2021-01-20 |
| AU2015301782B2 (en) | 2020-09-03 |
| AU2015301782A1 (en) | 2017-03-02 |
| JP6545788B2 (ja) | 2019-07-17 |
| US10098854B2 (en) | 2018-10-16 |
| IL250490A0 (en) | 2017-03-30 |
| CA2957926A1 (en) | 2016-02-18 |
| JP2017524719A (ja) | 2017-08-31 |
| KR20170040800A (ko) | 2017-04-13 |
| IL279627A (en) | 2021-03-01 |
| EP3179993A1 (en) | 2017-06-21 |
| MA40462A (fr) | 2017-06-21 |
| EP3179993A4 (en) | 2018-03-28 |
| WO2016025581A1 (en) | 2016-02-18 |
| US20160045455A1 (en) | 2016-02-18 |
| CN106714789A (zh) | 2017-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2017001908A (es) | Metodo para el tratamiento de la depresion. | |
| MX2016005003A (es) | Marcadores geneticos predictivos de respuesta al acetato de glatiramero. | |
| MX2016012718A (es) | Determinación de polimorfismos de un solo nucleótido útil para predecir la respuesta para rasagilina. | |
| RU2014110824A (ru) | Способ прогнозирования риска невынашивания первой половины беременности | |
| UA95592U (uk) | Спосіб прогнозування зрощення перелому | |
| UA95658U (uk) | Спосіб прогнозування зрощення перелому | |
| UA95978U (uk) | Спосіб прогнозування зрощення перелому | |
| UA95591U (uk) | Спосіб прогнозування зрощення перелому | |
| UA106879U (uk) | Спосіб прогнозування зрощення перелому | |
| UA106318U (uk) | Спосіб прогнозування зрощення перелому | |
| UA106731U (uk) | Спосіб прогнозування зрощення перелому | |
| UA104426U (uk) | Спосіб прогнозування зрощення перелому | |
| UA95656U (uk) | Спосіб прогнозування зрощення перелому | |
| UA96535U (uk) | Спосіб прогнозування зрощення перелому | |
| UA97860U (uk) | Спосіб прогнозування зрощення перелому | |
| UA95604U (uk) | Спосіб прогнозування зрощення перелому | |
| UA106779U (uk) | Спосіб прогнозування зрощення перелому | |
| UA95603U (uk) | Спосіб прогнозування зрощення перелому | |
| UA96640U (uk) | Спосіб прогнозування зрощення перелому | |
| UA95971U (uk) | Спосіб прогнозування зрощення перелому | |
| UA96128U (uk) | Спосіб прогнозування зрощення перелому | |
| UA96666U (uk) | Спосіб прогнозування зрощення перелому | |
| UA96985U (uk) | Спосіб прогнозування зрощення перелому | |
| UA106212U (uk) | Спосіб прогнозування зрощення перелому | |
| UA96679U (uk) | Спосіб прогнозування зрощення перелому |